Multiple myeloma - lenalidomide (post bortezomib) (part rev TA171): Evaluation report

Please be advised that the format of evaluation reports shared on the NICE website has recently changed, for ease of user navigation between individual documents contained in the report.

It is a requirement of the new (PDF portfolio) format that Adobe Reader is used to view the document. Please follow the link at the bottom of this page to download Adobe Reader if required.

If you have any feedback on the new format please contact the Project Manager for this appraisal.

01 - Pre-Meeting Briefing

02 - Final Scope and Final Matrix of Consultees and Commentators

03 - Manufacturers submission

04 - NICE request to the manufacturer for clarification

05 - Manufacturer's response to NICE's request for clarification

06 - NICE request to the manufacturer for further clarification

07 - Manufacturer's response to the request for further clarification

08 - Consultee submission from Myeloma UK

09 - Clinical expert personal perspective - Davies

10 - Patient expert personal perspective - Dewinter

11 - Patient expert personal perspective - Low

12 - Evidence Review Group report

13 - Erratum to the Evidence Review Group report

14 - Manufacturer factual accuracy check of Evidence Review Group report

15 - ERG response to the manufacturer factual accuracy check



This page was last updated: 13 March 2014